<DOC>
	<DOCNO>NCT02227862</DOCNO>
	<brief_summary>To test whether Mylan 's insulin glargine daily non-inferior Lantus® daily ( base change HbA1c baseline 24 week ) administer combination mealtime insulin lispro .</brief_summary>
	<brief_title>Non-inferiority Study Compare Efficacy Safety Mylan 's Insulin Glargine With Lantus® Type 1 Diabetes Mellitus Patients ( INSTRIDE 1 )</brief_title>
	<detailed_description>This trial multicenter , open-label , randomize , parallel-group trial patient Type 1 Diabetes Mellitus ( T1DM ) compare efficacy safety Mylan 's insulin glargine Lantus® .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Patients establish diagnosis T1DM per ADA 2014 criterion Body mass index ( BMI ) 18.5 35 kg/m2 screening ( value inclusive ) . Glycosylated hemoglobin ( HbA1c ) ≤9.5 % screening . Hemoglobin ≥9.0 g/dL screen . History hypersensitivity active inactive ingredient insulin/insulin analogue preparation use trial , OR history significant allergic drug reaction . History use animal insulin within last 3 year use biosimilar insulin glargine time prior . History use regular immunomodulator therapy 1 year prior screen . History ≥2 episodes severe hypoglycemia within 6 month screen history hypoglycemia unawareness ( sample questionnaire provide Appendix I ) , judge investigator . History ≥1 episodes diabetic ketoacidosis emergency room visit uncontrolled diabetes lead hospitalization within 6 month prior screen . Serological evidence human immunodeficiency virus ( HIV ) , hepatitis B ( HbSAg ) hepatitis C ( HCVAb ) antibodies screen . History drug alcohol dependence abuse 1 year prior screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>